A Randomized, Single Blind, Single Dose, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous Dosage Form of LCB01-0371 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs LCB01-0371 (Primary) ; LCB01-0371 (Primary)
- Indications Gram-positive infections
- Focus Pharmacokinetics
- Sponsors LegoChem Biosciences
- 10 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 10 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
- 10 Mar 2017 Status changed from not yet recruiting to recruiting.